Scopus

Documents

Chiang, J.C.B.[a] , Zahari, I.[b c] , Markoulli, M.[a] , Krishnan, A.V.[d] , Park, S.B.[e] , Semmler, A.[b] , Goldstein, D.[f] , Edwards, K.[b]

The impact of anticancer drugs on the ocular surface
(2020) *Ocular Surface*, 18 (3), pp. 403-417. Cited 12 times.

DOI: 10.1016/j.jtos.2020.03.008

[a] School of Optometry & Vision Science, University of New South Wales, Sydney, Australia
[b] Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
[c] Department of Optometry & Visual Science, International Islamic University Malaysia, Kuantan, Malaysia
[d] Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
[e] Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
[f] Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia

Abstract
Cancer is a global health problem and is one of the leading causes of death worldwide. Pleasingly, the rate of survival has improved and continues in an upward trend mainly due to better diagnosis and treatment modalities. In particular, the development of anticancer drugs including cytotoxic chemotherapy, hormonal agents and targeted therapies have provided the most effective treatment options in combatting cancerous cells. However, the antineoplastic mechanisms of these drugs can also lead to undesirable systemic and ocular side effects resulting from cytotoxicity, inflammation and neurotoxicity. While survival rates are projected to increase with time, the number of patients presenting with these side effects that can substantially impact quality of life will also rise. The current paper reviews the ocular surface and adnexal side effects of anticancer drugs, the appropriate management and possible interactions between drugs for ocular surface pathology treatment and the anticancer drugs. © 2020 Elsevier Inc.

Author Keywords
Anticancer drugs; Chemotherapy; Drug interactions; Hormonal agents; Ocular adnexa; Ocular side effects; Ocular surface; Targeted therapies

Index Keywords
agents acting on the eye, antineoplastic agent, antineoplastic hormone agonists and antagonists, antineoplastic monoclonal antibody, cytotoxic agent, phosphotransferase inhibitor, antineoplastic agent; anterior eye segment, biochemistry, biophysics, cancer chemotherapy, cancer hormone therapy, conjunctiva, conjunctiva disease, cornea, cornea disease, cornea erosion, cornea verticillata, corneal deposit, disease association, drug safety, eye toxicity, eyelash, eyelid, eyelid disease, human, lacrimal apparatus, lacrimal gland disease, molecularly targeted therapy, nonhuman, ocular surface disease, pharmacodynamics, pharmacokinetic parameters, punctate keratitis, Review, side effect, superficial punctate keratitis, symptom, tear film, eye, quality of life; Antineoplastic Agents, Eye, Humans, Quality of Life

Chemicals/CAS
Antineoplastic Agents

References

- National Cancer Institute
  Cancer statistics
  (2018), National Institute of Health
- Australian Cancer Research Foundation
  Cancer statistics
  (2018), Australian Cancer Research Foundation Sydney
- Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M.
  Effect of screening and adjuvant therapy on mortality from breast cancer
  (2005) *N Engl J Med*, 353, pp. 1784-1792.
- Schmid, K.E., Kornek, G.V., Scheithauer, W., Binder, S.
  Update on ocular complications of systemic cancer chemotherapy
  (2006) *Surv Ophthalmol*, 51, pp. 19-40.

- Ho, W.L., Wong, H., Yau, T.
  The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
  (2013) *Acta Ophthalmol*, 91, pp. 604-609.

- AusDI 2019
  Interactions and safety. Last retrieved November 21st
  (2019),

- Australian Medicines Handbook 2019
  Drug interactions. Last retrieved November 21st
  (2019),

- (2019) *eviQ cancer treatments online 2019*,
  Cancer Institute NSW Last retrieved November 5th

- Moosa, A., Dobish, R., Watts, C.
  Interacting with drugs used in oncology: an Alberta Cancer Board initiative
  (2003) *J Oncol Pharm Pract*, 9, pp. 87-107.

- Aldred, E.M.
  Pharmacology : a handbook for complementary healthcare professionals
  (2008), Elsevier Health Sciences London, United Kingdom

- Smith, J.A., Slusher, B.S., Wozniak, K.M., Farah, M.H., Smiyun, G., Wilson, L.
  Structural basis for induction of peripheral neuropathy by microtubule-targeting cancer drugs
  (2016) *Canc Res*, 76, pp. 5115-5123.

- Al-Tweigeri, T., Nabholtz, J.-M., Mackey, J.R.
  Ocular toxicity and cancer chemotherapy: a review
  (1996) *Cancer*, 78, pp. 1359-1373.

- Yu, F., Bender, W.
  The mechanism of tamoxifen in breast cancer prevention
  (2001) *Breast Cancer Res*, 3, p. A74.

- Plourde, P.V., Dyroff, M., Dukes, M.
  Arimidex: a potent and selective fourth-generation aromatase inhibitor
  (1994) *Breast Canc Res Treat*, 30, pp. 103-111.

- Gerber, D.E.
  Targeted therapies: a new generation of cancer treatments
  (2008) *Am Fam Physician*, 77, pp. 311-319.

- Bron, A.J., de Paiva, C.S., Chauhan, S.K., Bonini, S., Gabison, E.E., Jain, S.
  TFOS DEWS II pathophysiology report
  (2017) *Ocul Surf*, 15, pp. 438-510.

- Dong, F., Call, M., Xia, Y., Kao, W.W.Y.
  Role of EGF receptor signaling on morphogenesis of eyelid and meibomian glands
  (2017) *Exp Eye Res*, 163, pp. 58-63.

- Tucker, S.M., Linberg, J.V.
  Vascular anatomy of the eyelids
  (1994) *Ophthalmology*, 101, pp. 1118-1121.

- Demetri, G.D., Von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J.
  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
  (2002) *N Engl J Med*, 347, pp. 472-480.

- Hensley, M.L., Ford, J.M.
Imatinib treatment: specific issues related to safety, fertility, and pregnancy
(2003) *Semin Hematol*, 40, pp. 21-25.

- Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P.
Cutaneous side-effects of kinase inhibitors and blocking antibodies
(2005) *Lancet Oncol*, 6, pp. 491-500.

- Tasigna (nilotinib)
Drug Label information. Novartis pharmaceuticals corporation
(2018), U.S. National Library of Medicine, National Institutes of Health

- Lauer, A.K., Wobig, J.L., Shults, W.T., Neuwelt, E.A., Wilson, M.W.
Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy
(1999) *Am J Ophthalmol*, 127, pp. 230-233.

- Goldberg, N.H., Romolo, J.L., Austin, E.H., Drake, J., Rosenberg, S.A.
Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate
(1978) *Cancer*, 41, pp. 52-55.

- Pietras, K., Östman, A., Sjöquist, M., Buchdunger, E., Reed, R.K., Heldin, C.-H.
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
(2001) *Canc Res*, 61, pp. 2929-2934.

- Methvin, A.B., Gausas, R.E.
Newly recognized ocular side effects of erlotinib
(2007) *Ophthalmic Plast Reconstr Surg*, 23, pp. 63-65.

- Kennedy, B.J.
Metabolic and toxic effects of mithramycin during tumor therapy
(1970) *Am J Med*, 49, pp. 494-503.

- Karamitsos, A., Kokkas, V., Goulas, A., Paraskevopoulos, P., Gougoulias, K., Karampatakis, V.
Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen
(2013) *Hippokratia*, 17, pp. 120-125.

- Melichar, B., Nemcova, I.
Eye complications of cetuximab therapy
(2007) *Eur J Canc Care*, 16, pp. 439-443.

- Tullo, A.B., Esmaeli, B., Murray, P.I., Bristow, E., Forsythe, B.J., Faulkner, K.
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials
(2005) *Eye*, 19, pp. 729-738.

- Albert, D.M., Wong, V.G., Henderson, E.S.
Ocular complications of vincristine therapy
(1967) *Arch Ophthalmol*, 78, pp. 709-713.

- Palkar, A.H., Nair, A.G., Desai, R.J., Potdar, N.A., Shinde, C.A.
Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy

(2015) *J Pediatr Ophthalmol Strabismus*, 52, pp. e34-e37.
Online

- Foerster, C.G., Cursiefen, C., Kruse, F.E.
Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)
(2008) *Cornea*, 27, pp. 612-614.

- Lane, K., Goldstein, S.M.
Erlotinib-associated trichomegaly
(2007) *Ophthalmic Plast Reconstr Surg*, 23, pp. 65-66.

- Alexandrescu, D.T., Kauffman, C.L., Dasanu, C.A.
Persistent hair growth during treatment with the EGFR inhibitor erlotinib
(2009) *Dermatol Online J*, 15.

- Dunnill, C.J., Al-Tameemi, W., Collett, A., Haslam, I.S., Georgopoulos, N.T.
A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention
(2018) *Oncol*, 23, pp. 84-96.

- Garibaldi, D.C., Adler, R.A.
Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab
(2007) *Ophthalmic Plast Reconstr Surg*, 23, pp. 62-63.

- Esmaeli, B., Valero, V., Ahmadi, M.A., Booser, D.
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect
(2001) *Ophthalmology*, 108, pp. 994-995.

- Brink, H., Beex, L.M.
Punctal and canalicular stenosis associated with systemic fluorouracil therapy
(1995) *Doc Ophthalmol*, 90, pp. 1-6.

- Matsumoto, Y., Dogru, M., Sato, E., Ibrahim, O., Tatematsu, Y., Ogawa, Y.
S-1 induces meibomian gland dysfunction
(2010) *Ophthalmology*, 117.
1275.e4-7

- Lee, V., Bentley, C.R., Olver, J.M.
Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy
(1998) *Eye*, 12, p. 343.

- Stevens, A., Spooner, D.
Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer
(2001) *Clin Oncol*, 13, pp. 438-440.

- Skolnick, C.A., Doughman, D.J.
Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere)
(2003) *Eye Contact Lens*, 29, pp. 134-135.

- Esmaeli, B., Diba, R., Ahmadi, M., Saadati, H., Faustina, M., Shepler, T.
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)
(2004) *Eye*, 18, pp. 760-762.

- Yanoff, M., Sassani, J.W.
7 - conjunctiva

(2015) *Ocular pathology*, pp. 199-225.e6.
M. Yanoff J.W. Sassani seventh ed. W.B. Saunders London

- (2015) *Eloxatin (oxaliplatin) injection for intravenous use [precribing information]*, pp. 1-14. Sanofi-Aventis U.S. LLC Bridgewater

- Choonara, I.A., Overend, M., Bailey, C.C.
Blurring of vision due to ifosfamide
(1987) *Canc Chemother Pharmacol*, 20, p. 349.

- Lochhead, J., Salmon, J.F., Bron, A.J.
Cytarabine-induced corneal toxicity
(2003) *Eye*, 17, p. 677.

- Kraut, E.H., Bouroncle, B., Grever, M.R.
Pentostatin in the treatment of advanced hairy cell leukemia
(1989) *J Clin Oncol*, 7, pp. 168-172.

- Lass, J.H., Lazarus, H.M., Reed, M.D., Herzig, R.H.
Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine
(1982) *Am J Ophthalmol*, 94, pp. 617-621.

- Hopen, G., Mondino, B.J., Johnson, B.L., Chervenick, P.A.
Corneal toxicity with systemic cytarabine
(1981) *Am J Ophthalmol*, 91, pp. 500-504.

- Curran, C.F., Luce, J.K.
Ocular adverse reactions associated with adriamycin (doxorubicin)
(1989) *Am J Ophthalmol*, 108, pp. 709-711.

- Martin, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massuti, B., Lizon, J.
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group
(2003) *Ann Oncol*, 14, pp. 833-842.

- Franca, R., Claudia, V., Francesco, R., Alessandra, I., Mariangela, C., Andrea, A.
Conjunctival hemorrhagic events associated with imatinib mesylate
(2007) *Int J Hematol*, 86, pp. 390-393.

- Sun, F., Cui, L., Li, T., Chen, S., Song, J., Li, D.
Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma
(2019) *J Recept Signal Transduct Res*, pp. 1-7.

- Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C.
Combination chemotherapy as an adjuvant treatment in operable breast cancer
(1976) *N Engl J Med*, 294, pp. 405-410.

- Agustoni, F., Platania, M., Vitali, M., Zilembo, N., Haspinger, E., Sinno, V.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders
(2014) *Canc Treat Rev*, 40, pp. 197-203.

- Steele, W.H., Stuart, J.F., Whiting, B., Lawrence, J.R., Calman, K.C., McVie, J.G.
Serum, tear and salivary concentrations of methotrexate in man
(1979) *Br J Clin Pharmacol*, 7, pp. 207-211.

- Esmaeli, B., Ahmadi, A., Rivera, E., Valero, V.
Docetaxel secretion in tears: association with lacrimal drainage obstruction
(2002) *Arch Ophthalmol*, 120, pp. 1180-1182.

- Hodges, R.R., Bair, J.A., Carozza, R.B., Li, D., Shatos, M.A., Dartt, D.A.
Signaling pathways used by EGF to stimulate conjunctival goblet cell secretion
(2012) *Exp Eye Res*, 103, pp. 99-113.

- Borkar, D.S., Lacouture, M.E., Basti, S.
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
(2013) *Support Care Canc*, 21, pp. 1167-1174.

- Tsuda, M., Takano, Y., Shigeyasu, C., Imoto, S., Yamada, M.
Abnormal corneal lesions induced by trastuzumab emtansine: an antibody–drug conjugate for breast cancer
(2016) *Cornea*, 35, pp. 1378-1380.

- Saint-Jean, A., Sainz de la Maza, M., Morral, M., Torras, J., Quintana, R., Molina, J.J.
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases
(2012) *Ophthalmology*, 119, pp. 1798-1802.

- Jack, M., Hicks, J.
Ocular complications in high-dose chemoradiotherapy and marrow transplantation
(1981) *Ann Ophthalmol*, 13, pp. 709-711.

- Yang, Q.C., Bao, J., Li, C., Tan, G., Wu, A.H., Ye, L.
A murine model of dry eye induced by topical administration of erlotinib eye drops
(2018) *Int J Mol Med*, 41, pp. 1427-1436.

- Iovieno, A., Lambiase, A., Moretti, C., Perrella, E., Bonini, S.
Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression
(2009) *Cornea*, 28, pp. 821-824.

- Garrana, R.M., Zieske, J.D., Assouline, M., Gipson, I.K.
Matrix metalloproteinases in epithelia from human recurrent corneal erosion
(1999) *Invest Ophthalmol Vis Sci*, 40, pp. 1266-1270.

- Loprinzi, C.L., Love, R.R., Garrity, J.A., Ames, M.M.
Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity
(1990) *Canc Invest*, 8, pp. 459-465.

- Akune, Y., Yamada, M., Shigeyasu, C.
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1
(2018) *Jpn J Ophthalmol*, 62, pp. 432-437.

- Waikhom, B., Fraunfelder, F.T., Henner, W.D.
Severe ocular irritation and corneal deposits associated with capecitabine use
(2000) *N Engl J Med*, 343, pp. 740-741.

- Zinchuk, O., Watanabe, M., Hayashi, N., Fukushima, A., Ueno, H.
A case of tamoxifen keratopathy
(2006) *Arch Ophthalmol*, 124, pp. 1046-1048.

- Yeh, S., Fine, H.A., Smith, J.A.
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma
(2009) *Cornea*, 28, pp. 699-702.

- Ahn, J., Wee, W.R., Lee, J.H., Hyon, J.Y.
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer
(2011) *Kor J Ophthalmol*, 25, pp. 355-357.

- Chia, P.L., John, T.
Vortex keratopathy presumed secondary to AZD9291
(2015) *J Thorac Oncol*, 10, pp. 1807-1808.

- Azkargorta, M., Soria, J., Acera, A., Iloro, I., Elortza, F.
Human tear proteomics and peptidomics in ophthalmology: toward the translation of proteomic biomarkers into clinical practice
(2017) *J Proteomics*, 150, pp. 359-367.

- Chatziralli, I., Sergentanis, T., Zagouri, F., Chrysikos, D., Ladas, I., Zografos, G.C.
Ocular surface disease in breast cancer patients using aromatase inhibitors
(2016) *Breast J*, 22, pp. 561-563.

- Kanie, S., Fujieda, M., Hitotsumachi, T., Suzuki, S., Morita, F., Hakoi, K.
Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs
(2017) *J Toxicol Sci*, 42, pp. 291-300.

- Kim, S., Yoo, Y.S., Kim, H.S., Joo, C.K., Na, K.S.
Changes of meibomian glands in the early stage of post hematopoietic stem cell transplantation
(2017) *Exp Eye Res*, 163, pp. 85-90.

- Giannaccare, G., Bonifazi, F., Sessa, M., Fresina, M., Arpinati, M., Bandini, G.
Dry eye disease is already present in hematological patients before hematopoietic stem cell transplantation
(2016) *Cornea*, 35, pp. 638-643.

- Giannaccare, G., Bonifazi, F., Sebastiani, S., Sessa, M., Pellegrini, M., Arpinati, M.
Meibomian gland dropout in hematological patients before hematopoietic stem cell transplantation
(2018) *Cornea*, 37, pp. 1264-1269.

- Kim, N., Kim, J.W., Baek, J.-H., Kim, J.-S., Choung, H.-K., Kim, T.-Y.
S-1–induced lacrimal drainage obstruction and its association with ingredients/metabolites of S-1 in tears and plasma: a prospective multi-institutional study
(2018) *Cancer Res Treat*, 50, pp. 30-39.

- Hande, K.R., Stein, R.S., McDonough, D.A., Greco, F.A., Wolff, S.N.
Effects of high-dose cytarabine
(1982) *Clin Pharmacol Ther*, 31, pp. 669-674.

- Baskin, U.Y., Amirfallah, U.A., Unal, U.O., Calibasi, U.G., Oztop, U.I.
Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report
(2015) *Am J Therapeut*, 22, pp. e36-e39.

- Tummanapalli, S.S., Willcox, M.D.P., Issar, T., Yan, A., Pisarcikova, J., Kwai, N.
Tear film substance P: a potential biomarker for diabetic peripheral neuropathy
(2019) *Ocul Surf*, 17, pp. 690-698.

- Schiffman, R.M., Christianson, M., Jacobsen, G., Hirsch, J.D., Reis, B.L.
Reliability and validity of the ocular surface disease index
(2000) *Arch Ophthalmol*, 118, pp. 615-621.

- Inglis, H., Boyle, F.M., Friedlander, M.L., Watson, S.L.
Dry eyes and AIs: if you don't ask you won't find out

(2015) *Breast*, 24, pp. 694-698.

- Gibson, E., Stapleton, F., Dear, R., Wolffsohn, J.S., Golebiowski, B.
  Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain
  (2019) *Ocul Surf*, 18, pp. 108-113.

- Li, W., Graham, A.D., Lin, M.C.
  Understanding ocular discomfort and dryness using the pain sensitivity questionnaire
  (2016) *PloS One*, 11.

- Crane, A.M., Feuer, W., Felix, E.R., Levitt, R.C., McClellan, A.L., Sarantopoulos, K.D.
  Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked pain
  (2017) *Br J Ophthalmol*, 101, p. 1238.

- Tabuse, H., Kashiwagi, H., Hamauchi, S., Tsushima, T., Todaka, A., Yokota, T.
  Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy
  (2016) *Gastric Cancer*, 19, pp. 894-901.

- Maesta, I., Nitecki, R., Horowitz, N.S., Goldstein, D.P., de Freitas Segalla Moreira, M., Elias, K.M.
  Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience
  (2018) *Gynecol Oncol*, 148, pp. 161-167.

- Jones, L., Downie, L.E., Korb, D., Benitez-Del-Castillo, J.M., Dana, R., Deng, S.X.
  TFOS DEWS II management and therapy report
  (2017) *Ocul Surf*, 15, pp. 575-628.

- Segal, E.M., Flood, M.R., Mancini, R.S., Whiteman, R.T., Friedt, G.A., Kramer, A.R.
  Oral chemotherapy food and drug interactions: a comprehensive review of the literature
  (2014) *J Oncol Pract*, 10, pp. e255-e268.

- Niwa, T., Imagawa, Y., Yamazaki, H.
  Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450
  (2014) *Curr Drug Metabol*, 15, pp. 651-679.

- Periti, P., Mazzei, T., Mini, E., Novelli, A.
  Pharmacokinetic drug interactions of macrolides
  (1992) *Clin Pharmacokinet*, 23, pp. 106-131.

- McCune, J.S., Hawke, R.L., LeCluyse, E.L., Gillenwater, H.H., Hamilton, G., Ritchie, J.
  In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
  (2000) *Clin Pharmacol Ther*, 68, pp. 356-366.

- van de Steeg, E., van Esch, A., Wagenaar, E., Kenworthy, K.E., Schinkel, A.H.
  Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice
  (2013) *Clin Canc Res*, 19, pp. 821-832.

- Iwaki, M., Shimada, H., Irino, Y., Take, M., Egashira, S.
  Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs
  (2017) *Biol Pharm Bull*, 40, pp. 926-931.

- Haas, A., Anderson, L., Lad, T.
The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients
(1983) *J Infect Dis*, 147, p. 363.

- Duan, J., Tao, J., Zhai, M., Li, C., Zhou, N., Lv, J.
Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives
(2018) *Oncotarget*, 9.
25738

- Thomas, S.H., Behr, E.R.
Pharmacological treatment of acquired QT prolongation and torsades de pointes
(2016) *Br J Clin Pharmacol*, 81, pp. 420-427.

- Coppola, C., Rienzo, A., Piscopo, G., Barbieri, A., Arra, C., Maurea, N.
Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs
(2018) *Canc Treat Rev*, 63, pp. 135-143.

- Pfizer Australia Pty Limited
Carboplatin injection product information
(2017), Therapeutic Goods Administration

- Sanja Pharmaceuticals Company
Carboplatin drug Label information
(2016), U.S. National Library of Medicine, National Institutes of Health

- Tierney, A.J., Leonard, R.C., Taylor, J., Closs, S.J., Chetty, U., Rodger, A.
Side effects expected and experienced by women receiving chemotherapy for breast cancer
(1991) *BMJ*, 302, p. 272.

- Eiseman, A.S., Flanagan, J.C., Brooks, A.B., Mitchell, E., Pemberton, C.H.
Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil
(2003) *Ophthalmic Plast Reconstr Surg*, 19, pp. 216-224.

- Accord Healthcare Inc
Fluorouracil drug Label information. U.S. National library of medicine, national institutes of health
(2017),

- Sandoz Pty Ltd
Fluorouracil ebewe product information
(2017), Therapeutic Goods Administration

- Parrozzani, R., Frizziero, L., Trainiti, S., Testi, I., Miglionico, G., Pilotto, E.
Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study
(2017) *Br J Ophthalmol*, 101, pp. 1094-1099.

- Joag, M.G., Sise, A., Murillo, J.C., Ahmed, I.O.-S., Wong, J.R., Mercado, C.
Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia
(2016) *Ophthalmology*, 123, pp. 1442-1448.

- Chaugule, S.S., Park, J., Finger, P.T.
Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: is surgery necessary?
(2018) *Indian J Ophthamol*, 66, pp. 55-60.

- Roche Products Pty Limited
Xeloda product information
(2016), Therapeutic Goods Administration

- Amneal Pharmaceuticals LLC
Capecitabine drug Label information
(2017), U.S. National Library of Medicine, National Institutes of Health

- Sandoz Pty Ltd
Methotrexate ebewe product information
(2016), Therapeutic Goods Administration

- Fresenius Kabi USA, LLC
Methotrexate drug Label information
(2016), U.S. National Library of Medicine, National Institutes of Health

- Yamagishi, T., Ochi, N., Yamane, H., Hasebe, S., Takigawa, N.
Epiphora in lung cancer patients receiving docetaxel: a case series
(2014) *BMC Res Notes*, 7, p. 322.

- Hospira Inc
Docetaxel drug Label information
(2017), U.S. National Library of Medicine, National Institutes of Health

- Pfizer Australia Pty Limited
Adriamycin solution for injection product information
(2014), Therapeutic Goods Administration

- Amneal Biosciences
Doxorubicin hydrochloride drug Label information
(2017), U.S. National Library of Medicine, National Institutes of Health

- Ejlertsen, B., Mouridsen, H.T., Jensen, M.-B., Andersen, J., Cold, S., Edlund, P.
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
(2007) *Eur J Canc*, 43, pp. 877-884.

- Huillard, O., Bakalian, S., Levy, C., Desjardins, L., Lumbroso-Le Rouic, L., Pop, S.
Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review
(2014) *Eur J Canc*, 50, pp. 638-648.

- Amgen Australia Pty Ltd
Vectibix product information
(2018), Therapeutic Goods Administration

- Amgen Inc
Vectibix drug Label information
(2017), U.S. National Library of Medicine, National Institutes of Health

- Merck Serono Pty Ltd
Erbitux product information
(2015), Therapeutic Goods Administration

- ImClone LLC
Erbitux drug Label information
(2018), U.S. National Library of Medicine, National Institutes of Health

- Orlandi, A., Fasciani, R., Cassano, A., Agresta, A., Calegari, M.A., Caporossi, A.
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind”

side effect in a case report
(2015) *BMC Canc*, 15, p. 973.

- Roche Products Pty Limited
Herceptin product information
(2018), Therapeutic Goods Administration

- Roche Products Pty Limited
Tarceva product information
(2012), Therapeutic Goods Administration

- Genentech Inc
Tarceva drug Label information
(2016), U.S. National Library of Medicine, National Institutes of Health

- AstraZeneca Pty Ltd
Iressa product information
(2018), Therapeutic Goods Administration

- AstraZeneca Pharmaceuticals LP
Iressa drug Label information
(2018), U.S. National Library of Medicine, National Institutes of Health

- Pfizer Australia Pty Limited
Sutent product information
(2018), Therapeutic Goods Administration

- Sanofi-Aventis Australia Pty Ltd
Caprelsa product information
(2016), Therapeutic Goods Administration

- Novartis Pharmaceuticals Australia Pty Ltd
Glivec product information
(2017), Therapeutic Goods Administration

- Novartis Pharmaceuticals
Gleevec drug Label information
(2018), U.S. National Library of Medicine, National Institutes of Health

- Moore, D.C., Muslimani, A., Sinclair, P.
Nilotinib-induced ocular toxicity: a case report
(2018) *Am J Therapeut*, 25, p. e570.

- Novartis Pharmaceuticals Pty Ltd
Tasigna product information
(2018), Therapeutic Goods Administration

- Beth, M., Kerr, H.
Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib
(2011) *Dermatol Ther*, 24, pp. 396-400.

Correspondence Address
Chiang J.C.B.; School of Optometry and Vision Science, Australia; email: jeremychungbo.chiang@unsw.edu.au

Publisher: Elsevier Inc.

ISSN: 15420124
PubMed ID: 32344148
Language of Original Document: English
Abbreviated Source Title: Ocul. Surf.
2-s2.0-85084141675
Document Type: Review
Publication Stage: Final
Source: Scopus